These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 28306192)

  • 21. Geldanamycin, radicicol, and chimeric inhibitors of the Hsp90 N-terminal ATP binding site.
    Hadden MK; Lubbers DJ; Blagg BS
    Curr Top Med Chem; 2006; 6(11):1173-82. PubMed ID: 16842154
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives.
    Kim T; Keum G; Pae AN
    Expert Opin Ther Pat; 2013 Aug; 23(8):919-43. PubMed ID: 23641970
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Spotlight on 17-AAG as an Hsp90 inhibitor for molecular targeted cancer treatment.
    Talaei S; Mellatyar H; Asadi A; Akbarzadeh A; Sheervalilou R; Zarghami N
    Chem Biol Drug Des; 2019 May; 93(5):760-786. PubMed ID: 30697932
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sensitization of multidrug-resistant human cancer cells to Hsp90 inhibitors by down-regulation of SIRT1.
    Kim HB; Lee SH; Um JH; Oh WK; Kim DW; Kang CD; Kim SH
    Oncotarget; 2015 Nov; 6(34):36202-18. PubMed ID: 26416354
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of E-cadherin in lung cancer and interaction with growth suppression by histone deacetylase inhibition.
    Kakihana M; Ohira T; Chan D; Webster RB; Kato H; Drabkin HA; Gemmill RM
    J Thorac Oncol; 2009 Dec; 4(12):1455-65. PubMed ID: 20009910
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and biological evaluation of geldanamycin analogs against human cancer cells.
    Li YP; Chen JJ; Shen JJ; Cui J; Wu LZ; Wang Z; Li ZR
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):773-82. PubMed ID: 25681003
    [TBL] [Abstract][Full Text] [Related]  

  • 27. P-Glycoprotein-mediated resistance to Hsp90-directed therapy is eclipsed by the heat shock response.
    McCollum AK; TenEyck CJ; Stensgard B; Morlan BW; Ballman KV; Jenkins RB; Toft DO; Erlichman C
    Cancer Res; 2008 Sep; 68(18):7419-27. PubMed ID: 18794130
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of 90-kD heat shock protein potentiates the cytotoxicity of chemotherapeutic agents in human glioma cells.
    Ohba S; Hirose Y; Yoshida K; Yazaki T; Kawase T
    J Neurosurg; 2010 Jan; 112(1):33-42. PubMed ID: 19408974
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alleviating neurodegeneration by an anticancer agent: an Hsp90 inhibitor (17-AAG).
    Waza M; Adachi H; Katsuno M; Minamiyama M; Tanaka F; Sobue G
    Ann N Y Acad Sci; 2006 Nov; 1086():21-34. PubMed ID: 17185503
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line.
    Price JT; Quinn JM; Sims NA; Vieusseux J; Waldeck K; Docherty SE; Myers D; Nakamura A; Waltham MC; Gillespie MT; Thompson EW
    Cancer Res; 2005 Jun; 65(11):4929-38. PubMed ID: 15930315
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells.
    Rouhi A; Miller C; Grasedieck S; Reinhart S; Stolze B; Döhner H; Kuchenbauer F; Bullinger L; Fröhling S; Scholl C
    Oncotarget; 2017 Jan; 8(5):7678-7690. PubMed ID: 28032595
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin.
    Bonvini P; Gastaldi T; Falini B; Rosolen A
    Cancer Res; 2002 Mar; 62(5):1559-66. PubMed ID: 11888936
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Using natural product inhibitors to validate Hsp90 as a molecular target in cancer.
    Neckers L
    Curr Top Med Chem; 2006; 6(11):1163-71. PubMed ID: 16842153
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modulation of melanoma cell phospholipid metabolism in response to heat shock protein 90 inhibition.
    Beloueche-Babari M; Arunan V; Jackson LE; Perusinghe N; Sharp SY; Workman P; Leach MO
    Oncotarget; 2010 Jul; 1(3):185-97. PubMed ID: 21037799
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of heat shock protein 90 destabilizes receptor tyrosine kinase ROR1 in lung adenocarcinoma.
    Khaledian B; Taguchi A; Shin-Ya K; Kondo-Ida L; Kagaya N; Suzuki M; Kajino T; Yamaguchi T; Shimada Y; Takahashi T
    Cancer Sci; 2021 Mar; 112(3):1225-1234. PubMed ID: 33370472
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Co-targeting AR and HSP90 suppresses prostate cancer cell growth and prevents resistance mechanisms.
    Centenera MM; Carter SL; Gillis JL; Marrocco-Tallarigo DL; Grose RH; Tilley WD; Butler LM
    Endocr Relat Cancer; 2015 Oct; 22(5):805-18. PubMed ID: 26187127
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-proliferative activity of heat shock protein (Hsp) 90 inhibitors via beta-catenin/TCF7L2 pathway in adult T cell leukemia cells.
    Kurashina R; Ohyashiki JH; Kobayashi C; Hamamura R; Zhang Y; Hirano T; Ohyashiki K
    Cancer Lett; 2009 Oct; 284(1):62-70. PubMed ID: 19464103
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.
    Zsebik B; Citri A; Isola J; Yarden Y; Szöllosi J; Vereb G
    Immunol Lett; 2006 Apr; 104(1-2):146-55. PubMed ID: 16384610
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The heat-shock protein 90 inhibitor, geldanamycin, induces apoptotic cell death in Epstein-Barr virus-positive NK/T-cell lymphoma by Akt down-regulation.
    Jeon YK; Park CH; Kim KY; Li YC; Kim J; Kim YA; Paik JH; Park BK; Kim CW; Kim YN
    J Pathol; 2007 Oct; 213(2):170-9. PubMed ID: 17768706
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dimeric ansamycins--a new class of antitumor Hsp90 modulators with prolonged inhibitory activity.
    Zhang H; Yang YC; Zhang L; Fan J; Chung D; Choi D; Grecko R; Timony G; Karjian P; Boehm M; Burrows F
    Int J Cancer; 2007 Feb; 120(4):918-26. PubMed ID: 17131314
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.